Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma

Significance Glioblastoma (GBM) cells develop intrinsic or acquired insensitiveness to BET bromodomain inhibitors (BBIs) yet develop persistent BET protein dependency. Selective degradation of BET proteins by a next-generation chemical compound undermines the BET protein dependency and exerts superior antineoplastic effects over inhibition of BET bromodomain. Given the significant difference between bromodomain dependency and BET protein dependency in GBM cells, chemically induced degradation of BET proteins serves as a promising strategy to overcome anticipated clinical BBIs resistance. Competitive BET bromodomain inhibitors (BBIs) targeting BET proteins (BRD2, BRD3, BRD4, and BRDT) show promising preclinical activities against brain cancers. However, the BET protein-dependent glioblastoma (GBM)-promoting transcriptional network remains elusive. Here, with mechanistic exploration of a next-generation chemical degrader of BET proteins (dBET6), we reveal a profound and consistent impact of BET proteins on E2F1- dependent transcriptional program in both differentiated GBM cells and brain tumor-initiating cells. dBET6 treatment drastically reduces BET protein genomic occupancy, RNA-Pol2 activity, and permissive chromatin marks. Subsequently, dBET6 represses the proliferation, self-renewal, and tumorigenic ability of GBM cells. Moreover, dBET6-induced degradation of BET proteins exerts superior antiproliferation effects compared to conventional BBIs and overcomes both intrinsic and acquired resistance to BBIs in GBM cells. Our study reveals crucial functions of BET proteins and provides the rationale and therapeutic merits of targeted degradation of BET proteins in GBM.

[1]  D. Faller,et al.  RING3 kinase transactivates promoters of cell cycle regulatory genes through E2F. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[2]  Łukasz M. Boryń,et al.  Transcriptional plasticity promotes primary and acquired resistance to BET inhibition , 2015, Nature.

[3]  James S. Duncan,et al.  Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer. , 2016, Cell reports.

[4]  Mark A. Dawson,et al.  BET inhibitor resistance emerges from leukaemia stem cells , 2015, Nature.

[5]  Christopher J. Ott,et al.  BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment. , 2017, Molecular cell.

[6]  J. Uhm,et al.  The transcriptional network for mesenchymal transformation of brain tumours , 2010 .

[7]  Siew Hong Leong,et al.  Cryopreservation of Neurospheres Derived from Human Glioblastoma Multiforme , 2009, Stem cells.

[8]  Yingle Liu,et al.  Brd2 is a TBP-associated protein and recruits TBP into E2F-1 transcriptional complex in response to serum stimulation , 2006, Molecular and Cellular Biochemistry.

[9]  S. J. Flint,et al.  The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription. , 2008, Molecular cell.

[10]  M. Ellis,et al.  Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer. , 2017, Cancer research.

[11]  James E. Bradner,et al.  Phthalimide conjugation as a strategy for in vivo target protein degradation , 2015, Science.

[12]  D. Farkas,et al.  Isolation of cancer stem cells from adult glioblastoma multiforme , 2004, Oncogene.

[13]  J. Rutka,et al.  Aurora kinase B/C inhibition impairs malignant glioma growth in vivo , 2012, Journal of Neuro-Oncology.

[14]  James E. Bradner,et al.  Response and resistance to BET bromodomain inhibitors in triple negative breast cancer , 2015, Nature.

[15]  Subha Madhavan,et al.  Rembrandt: Helping Personalized Medicine Become a Reality through Integrative Translational Research , 2009, Molecular Cancer Research.

[16]  Webster K. Cavenee,et al.  EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling. , 2015, Molecular cell.

[17]  A. Belkina,et al.  BET domain co-regulators in obesity, inflammation and cancer , 2012, Nature Reviews Cancer.

[18]  Reid C Thompson,et al.  Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma , 2013, Clinical Cancer Research.

[19]  J. Sarkaria,et al.  The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation , 2015, Proceedings of the National Academy of Sciences.

[20]  F. Lang,et al.  ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo. , 2007, Cancer research.

[21]  C. Crews,et al.  Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. , 2015, Chemistry & biology.

[22]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[23]  T. Cloughesy,et al.  Glioblastoma: from molecular pathology to targeted treatment. , 2014, Annual review of pathology.

[24]  Andrew P. Stubbs,et al.  Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. , 2009, Cancer research.

[25]  Claes Wahlestedt,et al.  BET bromodomain proteins are required for glioblastoma cell proliferation , 2014, Epigenetics.

[26]  P. Wei,et al.  AURKA Governs Self-Renewal Capacity in Glioma-Initiating Cells via Stabilization/Activation of β-catenin/Wnt Signaling , 2013, Molecular Cancer Research.

[27]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[28]  Charles Y. Lin,et al.  Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. , 2013, Cancer cell.

[29]  S. Müller,et al.  An epigenetic screening determines BET proteins as targets to suppress self-renewal and tumorigenicity in canine mammary cancer cells , 2019, Scientific Reports.

[30]  E. Campo,et al.  Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma , 2014, Leukemia.

[31]  Qiang Zhou,et al.  Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. , 2005, Molecular cell.

[32]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[33]  H. Wakimoto,et al.  Polo‐Like Kinase 1 Inhibition Kills Glioblastoma Multiforme Brain Tumor Cells in Part Through Loss of SOX2 and Delays Tumor Progression in Mice , 2012, Stem cells.

[34]  S. Robson,et al.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.

[35]  L. Ouafik,et al.  OTX015 (MK‐8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models , 2016, International journal of cancer.